About Strand Therapeutics

Strand Therapeutics develops programmable, long-acting mRNA therapeutics that utilize logic-based circuits to target and activate treatments specifically in diseased cells. This technology addresses the challenge of delivering precise, multi-functional therapies while minimizing off-target effects, aiming to improve treatment outcomes for cancer and other life-threatening diseases.

```xml <problem> Current mRNA therapies lack precise control over where and when they are active, leading to potential off-target effects and limiting their therapeutic window. This lack of specificity can result in toxicity and reduced efficacy, especially when treating diseases like cancer that require targeted intervention. </problem> <solution> Strand Therapeutics is developing a platform for programmable mRNA therapeutics that uses synthetic biology to control the location, timing, intensity, and duration of protein expression. By incorporating logic-based circuits into mRNA, the therapeutics can sense different cell types and only activate in diseased cells. This approach increases the therapeutic window by allowing the mRNA to travel throughout the body while ensuring its therapeutic protein payload acts only in the appropriate locations, turning off in healthy cells. Strand's self-replicating mRNAs aim to provide improved treatment options for cancer and other life-threatening diseases. </solution> <features> - Programmable mRNA therapeutics with logic-based circuits for precise control of protein expression - Ability to sense different cell types and activate only in diseased cells - Self-replicating mRNAs for long-acting therapeutic effects - Bioengineered to control the location, timing, intensity, and duration of protein expression - Potential for multi-functional and curative treatments </features> <target_audience> The primary target audience includes patients with cancer and other life-threatening diseases, as well as pharmaceutical companies seeking to develop more targeted and effective mRNA therapies. </target_audience> ```

What does Strand Therapeutics do?

Where is Strand Therapeutics located?

Strand Therapeutics is based in Cambridge, United Kingdom.

When was Strand Therapeutics founded?

Strand Therapeutics was founded in 2017.

How much funding has Strand Therapeutics raised?

Strand Therapeutics has raised 102560000.

Location

Cambridge, United Kingdom

Founded

2017

Funding

102560000

Employees

93 employees

Major Investors

FPV Ventures

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Strand Therapeutics

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

strandtx.com 10K+

Crunchbase

Founded 2017 – Cambridge, United Kingdom

Funding

Estimated Funding

$100M+

Major Investors

FPV Ventures

Team (75+)

No team information available.

Company Description

Problem

Current mRNA therapies lack precise control over where and when they are active, leading to potential off-target effects and limiting their therapeutic window. This lack of specificity can result in toxicity and reduced efficacy, especially when treating diseases like cancer that require targeted intervention.

Solution

Strand Therapeutics is developing a platform for programmable mRNA therapeutics that uses synthetic biology to control the location, timing, intensity, and duration of protein expression. By incorporating logic-based circuits into mRNA, the therapeutics can sense different cell types and only activate in diseased cells. This approach increases the therapeutic window by allowing the mRNA to travel throughout the body while ensuring its therapeutic protein payload acts only in the appropriate locations, turning off in healthy cells. Strand's self-replicating mRNAs aim to provide improved treatment options for cancer and other life-threatening diseases.

Features

Programmable mRNA therapeutics with logic-based circuits for precise control of protein expression

Ability to sense different cell types and activate only in diseased cells

Self-replicating mRNAs for long-acting therapeutic effects

Bioengineered to control the location, timing, intensity, and duration of protein expression

Potential for multi-functional and curative treatments

Target Audience

The primary target audience includes patients with cancer and other life-threatening diseases, as well as pharmaceutical companies seeking to develop more targeted and effective mRNA therapies.